Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder.

Related Articles

Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder.

Expert Opin Drug Metab Toxicol. 2018 Aug 24;:

Authors: Hebbrecht K, Morrens M, Neels H, Roosens L, Sabbe BGC

Abstract
Introduction Bipolar disorder is a severe, chronic psychiatric disorder with a need for long-term treatment. Patient non-adherence is frequent and poses a major problem in maintenance therapy. Aripiprazole once-monthly long-acting injectable (AOM LAI) is a recently FDA approved treatment option for maintenance therapy that could be of great value. Areas covered This paper reviews the pharmacokinetic, efficacy and safety data for AOM LAI in bipolar disorder. Expert opinion AOM LAI is a safe and efficacious treatment option in the maintenance therapy of bipolar I disorder. However, further research is still needed to determine the position of AOM LAI relative to other available treatment options.

PMID: 30141352 [PubMed - as supplied by publisher]